Denis M. Callewaert
Founder at Oxford Biomedical Research, Inc.
Denis M. Callewaert active positions
Companies | Position | Start | End |
---|---|---|---|
Oxford Biomedical Research, Inc.
Oxford Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Oxford Biomedical Research (OBR) develops, manufactures and markets assay kits, recombinant proteins and antibodies for biomedical research and drug discovery. The company's primary focus is on the identification and assay of biomarkers for oxidative stress and chronic inflammation, two major risk factors for multiple diseases. OBR is employing proprietary technology to develop tissue and disease specific biomarkers. ProteoMine™ is a cost effective tool for removing high abundance proteins for biomarker discovery. ToxProfiler™ technology captures and detects oxidized proteins in blood correlated with organ-specific toxicity and disease. New platform technologies such as Toxic proteomics and Metabolomics are being applied, adapted and modified into new and practical ways for the diagnosis of early onset disease and for the prevention of diseases. The company was founded in 1984 and is headquartered in Rochester Hills, MI. | Founder | 17/05/2011 | - |
Career history of Denis M. Callewaert
Former positions of Denis M. Callewaert
Companies | Position | Start | End |
---|---|---|---|
ZIVO BIOSCIENCE, INC. | Chief Tech/Sci/R&D Officer | 22/04/2010 | - |
Training of Denis M. Callewaert
Oakland University (Michigan) | Doctorate Degree |
Statistics
International
United States | 4 |
Operational
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Founder | 1 |
Sectoral
Health Technology | 2 |
Consumer Services | 2 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
ZIVO BIOSCIENCE, INC. | Health Technology |
Private companies | 1 |
---|---|
Oxford Biomedical Research, Inc.
Oxford Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Oxford Biomedical Research (OBR) develops, manufactures and markets assay kits, recombinant proteins and antibodies for biomedical research and drug discovery. The company's primary focus is on the identification and assay of biomarkers for oxidative stress and chronic inflammation, two major risk factors for multiple diseases. OBR is employing proprietary technology to develop tissue and disease specific biomarkers. ProteoMine™ is a cost effective tool for removing high abundance proteins for biomarker discovery. ToxProfiler™ technology captures and detects oxidized proteins in blood correlated with organ-specific toxicity and disease. New platform technologies such as Toxic proteomics and Metabolomics are being applied, adapted and modified into new and practical ways for the diagnosis of early onset disease and for the prevention of diseases. The company was founded in 1984 and is headquartered in Rochester Hills, MI. | Commercial Services |
- Stock Market
- Insiders
- Denis M. Callewaert
- Experience